comprehensive -WSS

comprehensive

author：leisure time 2025-09-09 19:30:57 - browse：35793

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Parkinson’s finding may lead to tests and, someday, treatments

WSS

Elizabeth Holmes banned from government health programs

AI generated plenty of interest at JPM but not a lot of trust

A new approach to psychiatric drug development

Longer MASH drug regimen improved liver, Akero study finds

Biden's 'march

Fetal cell organoids grown from amniotic fluid, study finds

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stem cell biologist probes earliest stages of human development

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: BridgeBio, Akero, and human embryo models

What does generative AI mean for health care? We asked experts

My yearlong odyssey to get my son’s ADHD medication covered

State Dept. review finds Biden bears some blame for Afghanistan failures

Think you might have Covid

explore

Pregnant women don't need prenatal multivitamins, study concludes

Francis Collins on trust in science and how Covid communications failed

Prior authorization will have to move faster under new Biden rule

New brain studies show LSD's effects on the brain in full color

Medicare drug price negotiation hearing pits pharma v Biden admin

AI generated plenty of interest at JPM but not a lot of trust

focus

explore

Wikipedia

focus